Cancer News and Research

Latest Cancer News and Research

Innovative model of breast cancer rehabilitation

The Prospective Surveillance Model, an innovative new model of breast cancer rehabilitation, is featured in a special supplement to the American Cancer Society's journal, Cancer released on April 6, 2012. The model addresses the numerous physical issues faced by women with breast cancer and offers hope for an improved quality of life for all women with breast cancer through rehabilitation and exercise.

18 Apr 2012

IMRT better than CRT for treatment of localized prostate cancer

A treatment for localized prostate cancer known as Intensity Modulated Radiation Therapy (IMRT) is better than conventional conformal radiation therapy (CRT) for reducing certain side effects and preventing cancer recurrence, according to a study published in the April 18, 2012 issue of the Journal of the American Medical Association.

18 Apr 2012

Bevacizumab added to chemotherapy for NSCLC does not improve survival in elderly patients

Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) - an approach approved by the FDA in 2006 - did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare, a new study by Dana-Farber Cancer Institute researchers has found.

18 Apr 2012

Failure rate of PIP silicone breast implants could be as high as 33.8%

New research published in the Journal of Plastic, Reconstructive and Aesthetic Surgery suggests that the failure rate of silicone breast implants manufactured by Poly Implant Prosth-se (PIP) could be as high as 33.8%.

18 Apr 2012

Surgery to remove only the tumor preferable to removing entire kidney

Kidney cancer patients who had only their tumor removed had better survival than patients who had their entire kidney removed, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

18 Apr 2012

Access reports positive interim results from MuGard Phase 4 clinical trial in oral mucositis

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and oncology supportive care, announced interim results from its ongoing MuGard Phase 4 clinical trial in oral mucositis.

18 Apr 2012

SBRT shortens radiation treatment time for gynecologic cancers

About 71,500 women in the United States are diagnosed with a gynecologic cancer every year, according to the Centers for Disease Control. Researchers from University Hospitals Case Medical Center have developed a more effective way to treat gynecologic cancers, shortening radiation treatment time from five weeks to three days. The method will be published in the Journal of Visualized Experiments (JoVE) on April 17.

18 Apr 2012

Role of inability to express emotions in cancer

A review published in the current issue of Psychotherapy and Psychosomatics raises the issue of the role of the inability to express emotions in cancer. Several interesting hypotheses emerge such as a possible link between alexithymia and the immune system, between alexithymia and quality of life, or between alexithymia, anxiety and depression.

18 Apr 2012

Tumor size helps predict survival in node-negative breast cancer patients

Research from investigators at The Cancer Institute of New Jersey (CINJ), UMDNJ-School of Public Health (SPH) and UMDNJ-Robert Wood Johnson Medical School, indicates that tumor size stratified by age, race and hormone receptor status helps predict survival in node-negative breast cancer patients.

18 Apr 2012

New brain cancer vaccine with material from own tumors proves effective in clinical trial

A new brain cancer vaccine tailored to individual patients by using material from their own tumors has proven effective in a multicenter phase 2 clinical trial at extending their lives by several months or longer. The patients suffered from recurrent glioblastoma multiforme-which kills thousands of Americans every year.

18 Apr 2012

Idera commences IMO-3100 Phase 2 clinical trial for psoriasis

Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.

18 Apr 2012

High intensity focused ultrasound to treat prostate cancer shows initial success

A new tumor treatment that involves heating it with highly focused ultrasound, may mean men with prostate tumors can be treated without an overnight stay in hospital and avoiding the distressing side effects associated with current therapies.

17 Apr 2012

More insight into tangled proteins in Alzheimer's disease

In Alzheimer's disease, brain neurons become clogged with tangled proteins. Scientists suspect these tangles arise partly due to malfunctions in a little-known regulatory system within cells. Now, researchers have dramatically increased what they know about this particular regulatory system in mice. Such information will help scientists better understand Alzheimer's and other diseases in humans and could eventually provide new targets for therapies.

17 Apr 2012

Tumor microenvironment contributes critically to drug response

It should be possible to significantly improve the response of common cancers to existing "classical" chemotherapy drugs, say scientists at Cold Spring Harbor Laboratory (CSHL), by introducing agents that alter the interaction of cancer cells with their immediate surroundings, called the tumor microenvironment.

17 Apr 2012

Caring for wife with breast cancer can affect men's health

Caring for a wife with breast cancer can have a measurable negative effect on men's health, even years after the cancer diagnosis and completion of treatment, according to recent research.

17 Apr 2012

ImmunoGen commences IMGN529 Phase I trial in NHL

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN529 product candidate.

17 Apr 2012

Individuals with low-quality genes may produce offspring with even more inferior chromosomes

Evolutionary biologists at the University of Toronto have found that individuals with low-quality genes may produce offspring with even more inferior chromosomes, possibly leading to the extinction of certain species over generations.

17 Apr 2012

New study describes therapeutic approach to halt cancer progression

A new study describes a therapeutic approach to halting cancer progression by exploiting a previously unrecognized "addiction" of leukemia cells to specific signaling molecules. The research, published by Cell Press online on April 16th in the journal Cancer Cell, identifies non-classical oncogenes critical for tumor development and survival, and describes a potentially less toxic strategy that selectively targets these molecules.

17 Apr 2012

MD Anderson to conduct 15th annual Sprint for Life event on May 5

Ovarian cancer survivors, their friends and families, local businesses, corporate teams and employees of The University of Texas MD Anderson Cancer Center will join forces May 5 at the 15th annual Sprint for Life 5K Run/Walk and Sprint for Sprouts Kids' Run. The approximately 3,000 participants will come together for a common cause: to build awareness of ovarian cancer and raise funds for research.

17 Apr 2012

Viewpoints: The missing debate on women; The true cost of care; Fair wages for home health aides

The Centers for Disease Control and Prevention just reported that the nation's teen pregnancy rate is at an all-time low. Increased contraceptive use appears to have played a significant role in the decline. The Guttmacher Institute estimates that without Title X services, hundreds of thousands more teenagers would become pregnant every year. Why does GOP presidential candidate Mitt Romney think eliminating the federal money for family planning - $327 million annually - is wise?

17 Apr 2012